Sanofi launches hostile bid for Medivation; potential value of $9.3bn; Pfizer steps in and buys Medivation
Sanofi has gone public with a $52.50 per share all-cash bid to acquire public biotech Medivation Inc. The offer, which values Medivation at about $9.3bn, was immediately rejected by Medivation's board.
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com